Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals Inc (NQ: ABOS )

2.310 -0.060 (-2.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. 
Via Benzinga
Earnings Outlook For Acumen Pharmaceuticals
Via Benzinga
Earnings Preview For Acumen Pharmaceuticals
Via Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another breakdown of the biggest pre-market stock movers as we check out all of the shares rising and falling on Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Earnings Scheduled For March 27, 2023
Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its... 
Via Benzinga
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023 
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
Earnings Preview: Acumen Pharmaceuticals
Acumen Pharmaceuticals (NASDAQ:ABOS) is set to give its latest quarterly earnings report on Monday, 2022-11-14. Here's what investors need to know before the announcement. Analysts estimate that Acumen... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.